NCT04447287View on ClinicalTrials.gov

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

November 25, 2020

Study Completion Date

November 25, 2020

Conditions
Opioid Use Disorder
Interventions
DRUG

ASP8062

Oral

DRUG

Placebo ASP8062

Oral

DRUG

buprenorphine/naloxone

Sublingual

Trial Locations (1)

66212

Altasciences Clinical Kansas, Inc., Overland Park

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT04447287 - A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder | Biotech Hunter | Biotech Hunter